<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>Iranian Biomedical Journal</title>
<title_fa>مجله بیومدیکال ایران</title_fa>
<short_title>IBJ</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ibj.pasteur.ac.ir</web_url>
<journal_hbi_system_id>1</journal_hbi_system_id>
<journal_hbi_system_user>admin</journal_hbi_system_user>
<journal_id_issn>1028-852X</journal_id_issn>
<journal_id_issn_online>2008-823X</journal_id_issn_online>
<journal_id_pii>-</journal_id_pii>
<journal_id_doi>10.61882/ibj</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid>-</journal_id_sid>
<journal_id_nlai>8888</journal_id_nlai>
<journal_id_science>-</journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1395</year>
	<month>12</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2017</year>
	<month>3</month>
	<day>1</day>
</pubdate>
<volume>21</volume>
<number>2</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa>Association of ABCB1 (C3435T) and ABCC1 (G2012T) Polymorphisms with Clinical Response to Atorvastatin in Iranian Patients with Primary Hyperlipidemia</title_fa>
	<title>Association of ABCB1 (C3435T) and ABCC1 (G2012T) Polymorphisms with Clinical Response to Atorvastatin in Iranian Patients with Primary Hyperlipidemia</title>
	<subject_fa>Molecular Genetics &amp; Genomics</subject_fa>
	<subject>Molecular Genetics &amp; Genomics</subject>
	<content_type_fa>مقاله کوتاه</content_type_fa>
	<content_type>Short Communication</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;p style=&quot;direction: ltr; &quot;&gt;&lt;strong&gt;Background:&amp;nbsp; &lt;/strong&gt;Atorvastatin is prescribed for the primary and the secondary prevention of coronary artery diseases. A wide variation in inter-individual statin response suggests that genetic differences may contribute to this variation. This study investigated the association of &lt;em&gt;ABCB1&lt;/em&gt; (C3435T) and &lt;em&gt;ABCC1&lt;/em&gt; (G2012T) polymorphisms with clinical response to atorvastatin in Iranian primary hyperlipidemic patients. &lt;strong&gt;Methods&lt;/strong&gt;: Individuals (n=179) with primary hypercholesterolemia were enrolled, and peripheral blood samples were collected. Genotyping of two polymorphisms were performed by amplification refractory mutation system PCR. &lt;strong&gt;Results:&lt;/strong&gt; Following four weeks of treatment, a significant reduction of LDL-C was observed in variant groups (CT+TT) of &lt;em&gt;ABCB1&lt;/em&gt; (&lt;em&gt;P&lt;/em&gt;=0.018) and wild-type group (GG) of &lt;em&gt;ABCC1 &lt;/em&gt;genes (&lt;em&gt;P&lt;/em&gt;=0.029). Logistic regression analysis revealed a significant difference between male and female responses to 10 mg/day atorvastatin (&lt;em&gt;P&lt;/em&gt;=0.004, odds ratio=0.2, CI 95%=0.06-0.6). &lt;strong&gt;Conclusion:&lt;/strong&gt; Our finding indicated that these polymorphisms may be attributed to LDL-C serum levels in the primary hypercholesterolemia patients receiving atorvastatin.&lt;/p&gt;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Hypercholesterolemia, Statin, Gene polymorphisms</keyword>
	<start_page>120</start_page>
	<end_page>125</end_page>
	<web_url>http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-617&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>Niusha</first_name>
	<middle_name></middle_name>
	<last_name>Behdad</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Pharmacotherapy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Javad</first_name>
	<middle_name></middle_name>
	<last_name>Kojuri</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Cardiology, Faculty of  Medicine, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Negar</first_name>
	<middle_name></middle_name>
	<last_name>Azarpira</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Amir</first_name>
	<middle_name></middle_name>
	<last_name>Masoomi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code></code>
	<orcid></orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Pharmacotherapy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>Soha</first_name>
	<middle_name></middle_name>
	<last_name>Namazi</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>snamazi@sums.ac.ir</email>
	<code></code>
	<orcid></orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Pharmacotherapy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
